StockData
DBV Technologies S.A. logo

DBV Technologies S.A. (DBVT) company profile

DBVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as DBVTF
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 6/30
$10.27−0.75 (-6.81%)

Close on Nov 16, 2026Market cap $645.75MP/E –Yield –

About DBV Technologies

Biological Products, (No Diagnostic Substances), SIC 2836

DBV Technologies is a clinical-stage biopharmaceutical company that develops epicutaneous immunotherapy treatments using a skin patch platform called Viaskin. The technology delivers microgram amounts of antigens through intact skin to activate immune cells without entering the bloodstream. The company's primary candidate is the Viaskin Peanut patch, which is evaluated for treating peanut allergies in toddlers and children. Additionally, the firm develops earlier-stage product candidates, including Viaskin Milk for cow's milk allergy and eosinophilic esophagitis. Its intended end users are pediatric patients suffering from severe food allergies, supported by parents, caregivers, allergists, and pediatricians.

The company conducts clinical research globally, evaluating hundreds of pediatric participants across multiple Phase 2 and Phase 3 clinical trials. Its clinical development and regulatory pursuits focus on the United States and the European Union. The text also references patient survey data gathered across eight European countries. The provided text does not disclose the company's headquarters.

Summary of the business section of DBV Technologies's latest annual report, written by StockData.

Company profile

Company

Legal name
DBV Technologies S.A.
Founded
2002
Headquarters
Chatillon, France
Address
107 Avenue De La Republique
Phone
330155427878
Employees
125, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
I0
Fiscal year ends
December 31
Auditor
Deloitte & Associes, Paris-La Defense

Stock & identifiers

Ticker
DBVT
Other tickers
DBVTF
Exchange
Nasdaq
IPO date
Oct 22, 2014
Shares outstanding
314M, Oct 26, 2026
Public float
$250.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-2 reverse, Jun 7, 2024
SEC CIK
1613780
CUSIP
23306J309
ISIN
US23306J3095
FIGI
BBG0076D3T39
Share class FIGI
BBG0076D3TV8
LEI
969500PVBQFWQKVDMD80
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Daniel TasseCHIEF EXECUTIVE OFFICER, Director17,094
Pharis MohideenChief Medical Officer144,531
Virginie BoucinhaChief Financial Officer70,000
Kevin Michael TrappChief Commercial Officer55,000
Philina LeeDirector–
Brothers Life Sciences LP BakerDirector1,200,369
Bros. Advisors (GP) LLC BakerDirector1,585,054
667, L.P.Director–
Felix BakerDirector–
Julian BakerDirector–
Bros. Advisors Lp BakerDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.36M$7.66M$1.36M$125–
FY2024$1.62M-$506.08K$639.61K$20–
FY2023$2.44M$978.12K$631.15K$62–
FY2022$2.79M$2.95M$789.22K$96–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payTotalvs. prior year
Daniel Tassé
Chief Executive Officer and Director
$600.00K$780.00K$1.92M$62.57K$3.36M+107%
Virginie Boucinha
Chief Financial Officer
$350.45K$249.70K$86.42K$381.49K$1.07M+133%
Pharis Mohideen
Chief Medical Officer
$590.79K$430.22K$118.82K$502.69K$1.64M+100%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 22, 2014
Offer price
$43.27
Securities offered
4,277,826
Gross proceeds
$185.10M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 20, 2015

“Per Share Per ADS Total(1) Public Offering Price $ 43.27 $ 21.64 $ 92,572,155 Underwriting Discount(2) $ 3.0289 $ 1.5148 $ 6,480,051 Proceeds to DBV (before expenses) $ 40.2411 $ 20.1252 $ 86,092,104 (1) Total gross proceeds from the global offering, including the French registered private placement, are $115,693,259.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

Corporate history

Events identified from SEC filings

See a number that looks wrong?